Medicare Formulary Coverage of Brand-Name Drugs and Therapeutically Interchangeable Generics. / Vijay, Aishwarya; Gupta, Ravi; Liu, Patrick; Dhruva, Sanket S.; Shah, Nilay D.; Ross, Joseph S.In: Journal of general internal medicine, Vol. 35, No. 6, 01.06.2020, p. 1928-1930.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Medicare Formulary Coverage of Brand-Name Drugs and Therapeutically Interchangeable Generics
AU - Vijay, Aishwarya
AU - Gupta, Ravi
AU - Liu, Patrick
AU - Dhruva, Sanket S.
AU - Shah, Nilay D.
AU - Ross, Joseph S.
N1 - Funding Information: In the past 36 months, Dr. Shah received research support through Mayo Clinic from the Food and Drug Administration to establish Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938); the Centers of Medicare and Medicaid Innovation under the Transforming Clinical Practice Initiative (TCPI); the Agency for Healthcare Research and Quality (R01HS025164; R01HS025402; R03HS025517); the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R56HL130496; R01HL131535); the National Science Foundation; and the Patient Centered Outcomes Research Institute (PCORI) to develop a Clinical Data Research Network (LHSNet); Dr. Ross received research support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing, from Medtronic, Inc. and the Food and Drug Administration (FDA) to develop methods for postmarket surveillance of medical devices (U01FD004585), from the Food and Drug Administration to establish Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938), from the Blue Cross Blue Shield Association to better understand medical technology evaluation, from the Centers of Medicare and Medicaid Services (CMS) to develop and maintain performance measures that are used for public reporting (HHSM-500-2013-13018I), from the Agency for Healthcare Research and Quality (R01HS022882), from the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R01HS025164), and from the Laura and John Arnold Foundation to establish the Good Pharma Scorecard at Bioethics International and the Collaboration on Research Integrity and Transparency (CRIT) at Yale; all remaining authors declare no potential competing interests. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
PY - 2020/6/1
Y1 - 2020/6/1
UR - http://www.scopus.com/inward/record.url?scp=85074503778&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074503778&partnerID=8YFLogxK
U2 - 10.1007/s11606-019-05432-6
DO - 10.1007/s11606-019-05432-6
M3 - Article
C2 - 31625043
AN - SCOPUS:85074503778
VL - 35
SP - 1928
EP - 1930
JO - Journal of General Internal Medicine
JF - Journal of General Internal Medicine
SN - 0884-8734
IS - 6